ALFA Finder| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 508.9 | 489.7 | 244.6 |
| Other income | 9.0 | 1.6 | 6.0 |
| Total income | 517.9 | 491.2 | 250.6 |
| Profit before exceptional items & tax | 28.6 | 28.3 | 9.7 |
| Profit before tax | 27.4 | 27.4 | 9.3 |
| Net profit | 17.7 | 18.6 | 6.9 |
| Operating margin | 5.3% | 5.6% | 3.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +156.50% |
|---|---|
| Net profit, quarter on quarter | -4.80% |
| Revenue, year on year | +108.10% |
| Operating profit, year on year | +429.70% |
| Operating profit, quarter on quarter | -26.60% |
BSE results filing, NSE: MUKKA. Figures extracted from the filing.
Mukka Proteins Ltd: key numbers
- Share price
- ₹27.36
- Market cap
- ₹820.8 Cr
- Revenue (annual)
- ₹1,449 Cr
- Net profit (annual)
- ₹52.06 Cr
- P/E (TTM)
- 11.9×Sector 25.2×
- Promoter holding
- 73.33%+0.00% QoQ
- FII holding
- 1.70%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mukka Proteins Ltd
All →Mukka Proteins Acquisition Worth ₹2.13 Cr
Mukka Proteins' board approved revised terms to acquire 85,200 equity shares, a 46% stake, in Swachha Eco Solutions for up to Rs 2.13 Crore. The unlisted waste-management company is not a related party.
- Value
- ₹2.13 Cr
- Execution
- Up to 31-03-2027
Mukka Proteins Other Announcement
Mukka Proteins filed its quarterly statement of deviation for funds raised through a preferential warrant issue, reporting no deviation. Utilisation of Rs. 11.75 Crore against the working capital object is shown for the quarter ended September 2026.
Mukka Proteins Board Meeting Date
Mukka Proteins intimated a board meeting on 07 Nov 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The trading window closure is also disclosed.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Mukka Proteins Other Announcement
The company submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI regulatory requirements.
Mukka Proteins Production Started
Mukka Proteins Limited announced its subsidiary, United Gulf Fishery Products LLC, has commenced commercial production in Oman. The facility will produce fish meal and oil.